key: cord-0789781-a7c66gnd authors: Epaulard, Olivier; Buisson, Marlyse; Nemoz, Benjamin; Maréchal, Marion Le; Terzi, Nicolas; Payen, Jean-François; Froidure, Marie; Blanc, Myriam; Mounayar, Anne-Laure; Quénard, Fanny; Pierre, Isabelle; Pavese, Patricia; Germi, Raphaele; Grossi, Laurence; Larrat, Sylvie; Poignard, Pascal; Lupo, Julien title: Persistence at one year of neutralising antibodies after SARS-CoV-2 infection: Influence of initial severity and steroid use date: 2021-10-20 journal: J Infect DOI: 10.1016/j.jinf.2021.10.009 sha: 96638ab4f0349c206d9d9ffb13fb5c93bbf0a716 doc_id: 789781 cord_uid: a7c66gnd nan Olivier Epaulard 1,2,3 , Marlyse Buisson 3,4 , Benjamin Nemoz 2,3,4 , Marion Le Maréchal 1,2 , Nicolas Terzi 5 , Jean-François Payen 6 We conducted a follow-up of NAb titres 6 months (217±19 days) and up to 1 year (377±12 days) after a RT-PCR proven infection in 67 patients, infected between March and April 2020. Quantitative detection of SARS-CoV-2 antibodies targeting S1-RBD was determined by the Siemens SARS-CoV-2 IgG (sCOVG) assay on the Atellica IM platform (Siemens, Munich, Germany). Neutralising antibody quantification was performed according to the previously published protocol (2), based on a pseudotyped virus entry assay using a luciferase reporter gene. Pseudo-virus displaying full-length SARS-CoV-2 spike protein (derived from USA-WA1/2020 strain) was produced in HEK293T cells and used to infect HeLa-ACE2 cells. The result from this assay is expressed as the serum dilution required to reduce infection by 50% (ID50). The study was approved by the Comité de Protection des Personnes Sud-Est I on 20 August 2020 (ref 2020-84). Mean age at positive RT-PCR was 59.8±12 years; 42 (67.5%) of patients were males. Regarding Covid-19 severity, 17 (25.4%) individuals did not require oxygen supplementation, 17 (25.4%) required oxygen at a maximum of 2 L/min, and 33 (49.2%) required more than 2 L/min oxygen, among whom 29 were admitted to an intensive care unit. Dexamethasone was used in 20 of these 33 patients during the acute Covid-19 phase, all in patients admitted to ICU. At the first sample (N=67), median Atellica serology titre was 11.0 U/mL [IQR: ]. It was correlated with age (p<0.001, rho=0.411) and severity (suppl. Table 1 ). Among those who required oxygen supplementation >2 L/min, there was no significant difference according to steroid use (suppl Table 1 (Fig. 1) ; the Atellica serology titres remained stable between the two dates for unvaccinated individuals but greatly increased among the vaccinated. Median ID50 neutralising titres was 268 [177-545], with the same difference as above according to vaccine status. Indeed, the median ID50 titre for patients vaccinated between the two samples was 742 vs 237 [122-320] for unvaccinated subjects (p<0.001) (Fig. 1) . This difference was observed throughout the different severity groups (Fig. 2) . There was no difference in titre according to the initial use of steroids (Suppl. table 1). Correlates of protection for Covid-19 are not completely established. However, the presence of NAb is associated with protection against many viral infections, and recent studies showed that the risk of SARS-CoV-2 reinfection was correlated with the NAb titres (3). NAb response have therefore been particularly explored, mostly in the first months after SARS-CoV-2 infection, with somehow contrasting results. We observed in our cohort that nearly all patients (65/67) had detectable NAb titres 7 months after their symptomatic SARS-CoV-2 infection, and that titres were stable between 6 months and 1 year (as measured by both EIA and neutralisation assay). Relatively few studies have yet assessed NAb titers 1 year after infection; in a cohort of of 73 subjects (4), only 43% of individuals had detectable NAb titres after 1 year (vs 98% of 25 subjects sampled at months 5-6); in contrast, in a cohort of 620 individuals (58% inpatients and 42% outpatients) (5), the proportion with detectable NAb was high (80 to 90%) at 1 month and stable at 13 months (70-85%); in another recent study (6) , 97% of 367 patients had detectable NAb against initial SARS-CoV-2 strain at 13 months. In these different studies, those with more severe Covid-19 had higher NAb titres, as observed in our participants. We did not observed a significant influence of steroid therapy at the acute phase on the long-term NAb titres; this had already been observed during earlier follow-up (<1 month) (7) . Although unintended when we designed the study, we observed the expected booster effect of the vaccine dose. This so-called "hybrid immunity" has been observed in previous studies (8) , leading the French health authorities to recommend in early 2021 that subjects with a past SARS-CoV-2 infection should receive only one instead of two doses of the mRNA-based vaccine or AstraZeneca TM ChAd-based vaccine (9) . Our study has several limitations, the first being its relatively small population size. Moreover, we did not assess the neutralising potency of NAb against the Delta variant, which is less efficiently targeted by NAb induced by an infection with the viral strains circulating in 2020. Indeed, a recent pooled analysis (10) concluded that the SARS-CoV-2 lineages Beta, Gamma, and Delta were less sensitive to NAb Persistence of humoral immune response to SARS CoV-2 up to 7 months post-infection: Cross-sectional study Clinical and laboratory characteristics of symptomatic healthcare workers with suspected COVID-19: a prospective cohort study Covid-19 Breakthrough Infections in Vaccinated Health Care Workers Declining Levels of Neutralizing Antibodies Against SARS-CoV-2 in Convalescent COVID-19 Patients One Year Post Symptom Onset Long-term Persistence of Neutralizing Antibodies to SARS-CoV-2 Following Infection Persistence of neutralizing antibodies a year after SARS-CoV-2 infection in humans concentration kinetics and antibody response in hospitalized COVID-19 patients: results from a prospective observational study Vaccine strategy against SARS-CoV-2 -Vaccination of people with a past history of Covid-19 Neutralizing antibodies against SARS-CoV-2 variants induced by natural infection or vaccination: a systematic review and pooled meta-analysis Under press Siemens Healthineers for Atellica sCOVG reagents offered free of charge. This work was supported by the Direction à la Recherche Clinique et à l'Innovation du CHU Grenoble Alpes, Grenoble, France. This funding source had not involvement in study design, in the collection, analysis and interpretation of data, in the writing of the report, and in the decision to submit the article for publication.